Peptide Injection Site Reaction: Normal vs Infection
What a peptide injection site reaction usually looks like, why GHK-Cu can sting, how to rotate injection sites, and the signs of infection or allergy that need care.
Last reviewed
The Vital angle
Vital saves the injection site with each dose log, shows when you last used each site, and suggests the next site from the areas you already use, with left and right sides in turn. You can tag an injection site reaction or an allergic reaction on the dose, with a severity and notes, so a clinician can see which site, product, and lot came before a reaction.
What a peptide injection site reaction is
A peptide injection site reaction is a local change in the skin where a subcutaneous shot went in. It can be redness, itching, a small bump, a bruise, mild warmth, or a short sting. Most reactions stay at the site and fade without treatment. A small number are the first sign of an infection or an allergic reaction, and those need care.
Label data give a sense of how common these reactions are with approved peptide drugs. In the Wegovy trials, 1.4% of people on semaglutide had injection site reactions, against 1.0% on placebo. In the Mounjaro placebo-controlled pool, the rate was 3.2% on tirzepatide and 0.4% on placebo. The Egrifta (tesamorelin) label reports a much higher rate: 25% on tesamorelin and 14% on placebo during the first 26 weeks. Those numbers come from controlled trials with pharmaceutical-grade product. They do not tell you what to expect from a compounded or "research" vial.
This guide explains what is usually normal, what is not, and how to keep a record that helps a clinician. It is not medical advice. Ask your prescriber or pharmacist about any reaction that worries you.
Common injection site reactions and what they look like
The labels and the MedlinePlus patient guide describe the same short list of local effects.
- Redness (erythema). A pink or red patch around the needle point. Usually small and gone within a day or two.
- Itching (pruritus). Often appears with redness. The Egrifta label lists erythema and pruritus as the most common site effects.
- A small injection site lump. A soft or slightly firm bump under the skin, sometimes from the fluid itself before it absorbs.
- Bruising. A small blood vessel under the skin was hit. It changes color and fades like any bruise.
- Brief pain or sting. Some solutions sting as they go in. The feeling usually stops within minutes.
MedlinePlus says some soreness at the site is normal. What matters is the direction of change: a normal reaction stays small and gets better. A reaction that grows, gets hotter, or gets more painful over the next one or two days is a different situation.
Why GHK-Cu can sting
GHK-Cu is a copper peptide. It is a common ingredient in topical cosmetic products, but it is not an FDA-approved drug for injection, and no controlled human trial has tested injected GHK-Cu. Reports of a GHK-Cu sting come mostly from user accounts and clinic blogs, not from published studies, so the cause is not established.
The FDA lists injectable GHK-Cu on its page of bulk drug substances that may present significant safety risks in compounding. On the version current as of April 22, 2026, it appears in the table of withdrawn nominations. The FDA notes a possible risk of immunogenicity, which means an immune reaction, because of aggregation and peptide-related impurities, and it notes limited data in humans. A move to that table is not an approval and not a finding of safety.
If a GHK-Cu injection stings, do not change the concentration, the volume, or the dilution on your own to make it hurt less. Those changes alter the amount in each draw. Ask the prescriber or pharmacist who supplied it. A sting that goes on for hours, or that comes with spreading redness, needs a clinician to look at it. Our guide on how to reconstitute peptides with BAC water explains why the mix and the draw must stay as your pharmacist wrote them.
Normal vs infection signs
The table below compares typical local reactions with signs that point to infection or allergy. It is a guide for when to call, not a way to diagnose yourself.
| Usually expected | Get it checked |
|---|---|
| Small redness that fades in a day or two | Redness that spreads or grows after 24 to 48 hours |
| Mild itching | Red streaks moving away from the site |
| A small bump that shrinks | A lump that is hot, hard, painful, or growing |
| A bruise that changes color | Pus, drainage, or an open sore |
| A sting that stops within minutes | Fever or chills |
| Soreness when you press the spot | Hives or rash away from the site |
MedlinePlus tells readers to call their provider for signs of infection, such as redness, swelling, red streaks, or fever. The Egrifta label says to get prompt medical attention and stop treatment if a hypersensitivity reaction is suspected. Its listed reactions include itching, redness, flushing, hives, and rash.
A lump that stays for weeks is also worth a visit. Repeated shots in the same spot can cause lipohypertrophy, a thick, rubbery area of fatty tissue. Insulin research, such as a Diabetes Technology Society update, links it to poor site rotation and needle reuse. Medicine injected into that tissue can absorb unevenly.
How to rotate injection sites
Site rotation is the step that labels and injection guidelines repeat most often. The Egrifta label tells patients to rotate sites to lower the risk of reactions. MedlinePlus tells readers to move at least 1 inch from the last spot each time.
- Use only the body areas that your prescriber or the product label approves. MedlinePlus lists the belly, the outer side of the upper thighs, and the upper arms. Some labels allow only the abdomen.
- Stay at least 2 inches away from the belly button.
- Move at least 1 inch from the last injection spot each time.
- Alternate left and right sides in a planned order.
- Do not inject into skin that is red, bruised, hard, scarred, or tender.
- Use a new sterile needle and syringe for every injection.
- Record the site after every dose, so the next shot goes somewhere else.
Our injection technique guide covers skin preparation, angle, and needle disposal. If you use a syringe instead of a pen, read U-40 vs U-100 syringes for peptides before you draw, because a syringe mix-up changes the amount you inject.
What makes a reaction more likely
Several factors can make a reaction more likely. Some you can change, and some you must take to your prescriber or pharmacist.
- Product quality. Vials sold as "research use only" are not made under pharmaceutical controls. Contamination, wrong content, or impurities can cause local reactions or infections. Our guide to peptide catalog source checks explains what a label can and cannot tell you.
- Technique. A needle that is reused, touched, or not sterile can carry bacteria into the skin.
- Same site, many times. Repeated injections in one spot raise the chance of bumps and lipohypertrophy.
- Storage and temperature. Follow your product's storage and warming instructions, and never heat a vial or pen.
- More than one product. If you inject more than one peptide, a reaction is harder to trace. Our guide on stacking peptides with a GLP-1 covers the extra unknowns.
When to get urgent care
Get emergency care right away for any of these signs:
- Swelling of the face, lips, tongue, or throat
- Trouble breathing or wheezing
- Feeling faint, dizzy, or a fast heartbeat soon after a shot
- Hives that spread over the body
Get medical care the same day for a site that is hot, swollen, and spreading, red streaks, pus, fever, or pain that gets worse instead of better. Tell the clinician every product you injected, where it came from, and the lot number. If a product is not an approved drug, say so. That fact changes what the clinician looks for.
Keep a record of each site and reaction
A short record makes a reaction easier to investigate. It does not make a product safer.
- Write down the product, the pharmacy or seller, and the lot number.
- Record the date, time, and exact site of each injection.
- Note any reaction with its size, color, and how long it lasted.
- Take a photo of the site on day one and again on day two if it changes.
- Bring the record to your appointment. Our guide on a dose log for a doctor visit shows what to include.
Wegovy® is a trademark of Novo Nordisk A/S. Mounjaro® is a trademark of Eli Lilly and Company. Egrifta® (tesamorelin) is a trademark of Theratechnologies. Vital is independent and not affiliated with these companies.
Things to watch
Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.
Injectable GHK-Cu
GHK-Cu is not an FDA-approved drug for injection, and no controlled human trial has tested it. The FDA notes a possible immunogenicity risk from aggregation and peptide-related impurities, and limited human data.
Peptides sold as "research use only"
These vials are not made under pharmaceutical quality controls. Contamination or wrong content can cause local reactions and infections.
Reused or non-sterile needles
MedlinePlus says to use a new needle and syringe each time. Reuse raises the risk of infection and, with repeated injections, lipohypertrophy.
Injecting the same spot repeatedly
Insulin research links poor site rotation to lipohypertrophy, and medicine can absorb unevenly from that tissue.
Changing the dilution to stop a sting
A new concentration changes the amount in each draw. Ask the prescriber or pharmacist before any change to how a vial is mixed or drawn.
Frequently asked questions
Small redness that stays at the site and fades within a day or two is a common local reaction. Redness that spreads, gets hotter, or grows after 24 to 48 hours needs a clinician to look at it.
The cause is not established, because no controlled human trial has tested injected GHK-Cu, and it is not an FDA-approved drug. Do not change the dilution on your own. Ask the prescriber or pharmacist who supplied it, and get care for a sting that lasts for hours or comes with spreading redness.
Signs include redness that spreads, red streaks, warmth, a hot or growing lump, pus or drainage, worsening pain, and fever or chills. MedlinePlus tells readers to call their provider for redness, swelling, red streaks, or fever.
A small bump from the injected fluid usually shrinks over a few days. A lump that is painful, hot, or growing needs care, and a firm or rubbery area that stays for weeks can be lipohypertrophy from repeated injections in one spot.
MedlinePlus says to move at least 1 inch from the last injection spot each time, and to stay at least 2 inches from the belly button. Use only the body areas that your prescriber or the product label approves.
Get emergency care for swelling of the face, lips, tongue, or throat, trouble breathing, faintness, or hives that spread over the body. These can be signs of a serious allergic reaction.
Sources
- Subcutaneous (SQ) injections · MedlinePlus, U.S. National Library of Medicine
- EGRIFTA WR (tesamorelin) prescribing information · U.S. Food and Drug Administration
- WEGOVY (semaglutide) prescribing information · U.S. Food and Drug Administration
- MOUNJARO (tirzepatide) prescribing information · U.S. Food and Drug Administration
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
- Lipohypertrophy and Insulin: An Update From the Diabetes Technology Society · NIH / NCBI
This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.
Track every shot, every change
Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.
More from the Library
Ozempic Constipation: Fiber, Fluids, and Warning Signs
Why constipation is common on Ozempic, Wegovy, Mounjaro, and Zepbound, how to add fiber and fluids without more bloating, what to ask your pharmacist, and the signs that need care now.
Ozempic Hair Loss: Why Shedding Happens and When It Stops
Hair shedding during GLP-1 weight loss is usually telogen effluvium, a delayed and temporary response to rapid weight loss. Here is what the labels report, the usual timeline, and what to check with your provider.
Ozempic Nausea Relief: What Helps and When to Call
Why nausea is the most common side effect of Ozempic, Wegovy, Mounjaro, and Zepbound, the meal and fluid habits that ease it, and the warning signs that need a call today.
GLP-1 Side Effects
The most common side effects of GLP-1 medications, why they happen, and the practical ways people manage nausea, constipation, fatigue, and sulfur burps.